The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for July 2017 (PDF).
This issue contains information on the risk of severe liver injury in patients using Daclizumab (Zinbryta®). This drug is used to treat multiple sclerosis and during use monthly liver checks are recommended. These checks also need to continue for four months after stopping treatment. Liver injury should be monitored for and considered in patients on this treatment pending review by their consultant.
In the summary of letters sent to healthcare professionals in June it is noted that there have been several changes to prescribing information for enoxaparin (Clexane®). The strength will now be noted in milligrams and units, with 1mg equivalent to 100iu. The dosage in treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) has been clarified and use in end stage renal disease is not recommended unless to prevent thrombus formation in haemodialysis patients.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Updated Pregabalin Prescribing Guidance||NICE Guidance - July 2017 »|